Final efficacy data from NORSE EIGHT expected in January 2025; Resubmission of the ONS-5010 BLA targeted for Q1 CY2025; Initial commercial launches in Europe planned to commence in first half of CY2025; and Potential for US FDA approval of ONS-5010 in second half of CY2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK: